Table 4.
Lenvatinib-related adverse events in the 35 patients with unresectable hepatocellular carcinoma.
| Adverse Event | Liver Transplantation Group # (n = 10) | Control Group (n = 25) | p Value | ||
|---|---|---|---|---|---|
| Any Grades | Grade 3 | Any Grades | Grade 3 | ||
| Hypertension | 4 (40.0%) | 1 (10.0%) | 12 (48.0%) | 3 (12.0%) | 0.98 |
| Diarrhea | 3 (30.0%) | 0 (0%) | 7 (28.0%) | 1 (4%) | 0.78 |
| Decreased appetite | 2 (20.0%) | 0 (0%) | 4 (16.0%) | 0 (0%) | 0.78 |
| Decreased body weight | 1 (10.0%) | 0 (0%) | 3 (12.0%) | 0 (0%) | 0.87 |
| Fatigue | 3 (30.0%) | 0 (0%) | 8 (32.0%) | 1 (4.0%) | 0.91 |
| Palmar-plantar erythrodysesthesia | 2 (20.0%) | 0 (0%) | 6 (24.0%) | 0 (0%) | 0.80 |
| Nausea | 1 (10.0%) | 0 (0%) | 3 (12.0%) | 0 (0%) | 0.87 |
| Vomiting | 1 (10.0%) | 0 (0%) | 2 (8.0%) | 0 (0%) | 0.85 |
| Skin rash | 1 (10.0%) | 0 (0%) | 3 (12.0%) | 0 (0%) | 0.87 |
# Lenvatinib used for tumor recurrence after liver transplantation.